amikacin has been researched along with ceftobiprole in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Amsler, KM; Bush, K; Davies, TA; Jacobs, MR; Shang, W | 1 |
Aggen, JB; Armstrong, ES; Diokno, R; Dozzo, P; Feeney, LA; Gliedt, MJ; Goldblum, AA; Gomez, M; Hildebrandt, DJ; Kubo, A; Linsell, MS; Lopez, S; Matias, RD; Miller, GH; Moser, HE; Wlasichuk, KB | 1 |
Davies, T; Decker-Burgard, S; Körber-Irrgang, B; Kresken, M; Läuffer, J | 1 |
1 trial(s) available for amikacin and ceftobiprole
Article | Year |
---|---|
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Skin Diseases, Bacterial; Staphylococcus | 2008 |
3 other study(ies) available for amikacin and ceftobiprole
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Synthesis and spectrum of the neoglycoside ACHN-490.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Enterobacteriaceae; Microbial Sensitivity Tests; Molecular Structure; Proteus mirabilis; Pseudomonas aeruginosa; Sisomicin | 2010 |
In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time-kill methodology.
Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Drug Synergism; Drug Therapy, Combination; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Stem Cells; Time Factors | 2011 |